Answers are grounded in this paper and cite their sources.
Background/Objectives: Nipple-sparing mastectomy (NSM) is increasingly performed in BRCA1/2 carriers, both for risk reduction and for treatment of breast cancer, but concern remains about glandular tissue left beneath the preserved nipple. We summarised the oncological outcomes of NSM in carriers. Methods: We searched PubMed/MEDLINE and Europe PubMed Central (Europe PMC) up to 30 September 2026, CENTRAL on 26 September 2026, and Embase on 7 November 2026 and screened the citations of relevant articles for series reporting outcomes of NSM in BRCA1/2 carriers. The outcomes were breast cancer diagnosed after risk-reducing NSM and locoregional recurrence after therapeutic NSM; cancers found at surgery were not counted. Proportions per woman were pooled with a binomial random-effects model (generalised linear mixed model, no continuity correction) and are reported as marginal (average-risk) and median-type (typical-study) proportions, with crude proportions, a beta-binomial model, follow-up strata, and approximate person-time analyses as checks. Two human reviewers went through all articles, with generative AI used only as an assistant, and the statistics were reviewed by a third author. Risk of bias was assessed with an adapted Joanna Briggs Institute checklist and certainty of evidence with GRADE. Results: Fifteen studies were included. After risk-reducing NSM, seven breast cancers occurred among 1215 women from eleven studies (crude proportion 0.58% (exact 95% CI 0.23–1.18%); model-based marginal proportion 0.60%, median-type 0.41% (95% CI 0.04–1.07%)); follow-up ranged from 33 to 129 months, and four of the seven cancers came from one international registry. After therapeutic NSM, locoregional recurrence occurred in 16 of 363 women from five studies (crude 4.4% (exact 95% CI 2.5–7.1%); model-based marginal proportion 4.3%, median-type 4.2% (95% CI 1.1–6.9%)); one study contributed 11 of the 16 events. Recurrence within the nipple–areolar complex was reported explicitly by only one study (none in 114 breasts). Sensitivity analyses yielded median-type proportions of 0.30% to 0.74% after risk-reducing NSM and 2.6% to 4.2% after therapeutic NSM. Risk of bias was moderate to high in most studies, and the certainty of the evidence was very low for both outcomes. Conclusions: In BRCA1/2 carriers, about 0.6% of women had breast cancer after risk-reducing NSM and about 4% had locoregional recurrence after therapeutic NSM, but follow-up was short and heterogeneous and the certainty of the evidence is very low. These data describe observed event frequencies and do not establish oncological safety or equivalence to other mastectomy techniques; longer prospective studies with time-to-event, gene-specific, and comparative reporting are needed.
No takes yet. Share an insight, caveat, or question.
Melnik et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: